There are currently 195 clinical trials in Saint Paul, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including United Hospital, Regions Hospital, Regions Hospital Cancer Care Center and Gillette Children's Specialty Healthcare. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383
Recruiting
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), n... Read More
Gender:
All
Ages:
Between 40 years and 79 years
Trial Updated:
04/23/2024
Locations: Fairview Health Services St Johns, Saint Paul, Minnesota
Conditions: Primary Prevention of Atherosclerotic Cardiovascular Disease
Register for Updates
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
NCT03742102
Recruiting
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
Gender:
Female
Ages:
Between 18 years and 130 years
Trial Updated:
04/23/2024
Locations: Research Site, Saint Paul, Minnesota
Conditions: Triple Negative Breast Neoplasms
Register for Updates
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
NCT03191149
Recruiting
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Regions Hospital, Saint Paul, Minnesota +1 locations
Conditions: Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Register for Updates
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
NCT06079398
Recruiting
This trial is a Phase 2, multicenter, double-blind, randomized (ratio 2:1 TransCon CNP vs. placebo), placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 μg CNP/kg of Navepegritide (TransCon CNP) administered SC once-weekly for 52 weeks in infants with genetically verified heterozygous ACH, aged 0 to < 2 years at the time of randomization.
Gender:
All
Ages:
Between 0 years and 2 years
Trial Updated:
04/22/2024
Locations: Ascendis Investigational Site, Saint Paul, Minnesota
Conditions: Achondroplasia
Register for Updates
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement
NCT03735667
Recruiting
To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR.
Gender:
All
Ages:
All
Trial Updated:
04/22/2024
Locations: St. Joseph's Hospital-St. Paul, Saint Paul, Minnesota
Conditions: Aortic Stenosis
Register for Updates
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
NCT04394858
Recruiting
This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Poly (adenosine diphosphate [ADP]-ribose) polymerases (PARPs) are proteins that help repair deoxyribonucleic acid (DNA) mutations. PARP inhibitors, such as olapar... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Regions Hospital, Saint Paul, Minnesota +1 locations
Conditions: Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma, Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8
Register for Updates
Parenting in 2 Worlds Multisite Trial
NCT06324318
Recruiting
This research study will test the effectiveness of a culturally grounded parenting intervention called Parenting in 2 Worlds (P2W). This intervention is designed for American Indian / Alaska Native (AI) parents/guardians of adolescents who reside in urban areas. This will be a multi-regional effectiveness trial across four regions: Northeast (Buffalo/Niagara), Midwest (St. Paul/Minneapolis), Mountain (Denver), and Southwest (Phoenix). There are four specific aims. First, this study will test the... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
04/19/2024
Locations: Ain Dah Yung Center, Saint Paul, Minnesota
Conditions: Parenting, Mental Health Wellness 1, Substance Use, Risky Health Behavior
Register for Updates
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT06103864
Recruiting
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Research Site, Saint Paul, Minnesota
Conditions: Breast Cancer
Register for Updates
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
NCT03996265
Recruiting
This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. Cancer and its treatment can cause fatigue. Giving bupropion may improve cancer related fatigue in cancer survivors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Regions Hospital, Saint Paul, Minnesota +1 locations
Conditions: Be Diagnosed With Cancer and Have Completed Systemic Therapy
Register for Updates
An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer
NCT05592483
Recruiting
This study will collect real-world clinical and patient reported outcomes (PRO) and diary data from eligible patients with documented Human Epidermal Growth Factor Receptor 2 (HER2+) [globally] or HER2-low [North America only] in routine clinical practice.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
04/17/2024
Locations: Research Site, Saint Paul, Minnesota
Conditions: Breast Cancer
Register for Updates
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NCT05108298
Recruiting
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Gender:
All
Ages:
Between 18 years and 39 years
Trial Updated:
04/16/2024
Locations: Regions Hospital, Saint Paul, Minnesota +1 locations
Conditions: Breast Cancer, NOS, CNS Primary Tumor, NOS, Cervical Cancer, NOS, Colorectal Cancer, NOS, Leukemia, NOS, Lymphoma, NOS, Miscellaneous Neoplasm, NOS, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS, Testicular Nonseminomatous Germ Cell Tumor, NOS, Thyroid Cancer, NOS, Melanoma, Bone Cancer, NOS
Register for Updates
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
NCT04266249
Recruiting
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or b... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: Regions Hospital, Saint Paul, Minnesota +1 locations
Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Register for Updates